Bangor Savings Bank’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-266
| Closed | -$188 | – | 604 |
|
|
2025
Q3 | $188 | Hold |
266
| – | – | ﹤0.01% | 537 |
|
|
2025
Q2 | $298 | Hold |
266
| – | – | ﹤0.01% | 531 |
|
|
2025
Q1 | $335 | Buy |
+266
| New | +$471 | ﹤0.01% | 532 |
|
|
2024
Q4 | – | Sell |
-267
| Closed | -$921 | – | 553 |
|
|
2024
Q3 | $921 | Hold |
267
| – | – | ﹤0.01% | 525 |
|
|
2024
Q2 | $1.35K | Hold |
267
| – | – | ﹤0.01% | 489 |
|
|
2024
Q1 | $2.26K | Hold |
267
| – | – | ﹤0.01% | 465 |
|
|
2023
Q4 | $1.09K | Hold |
267
| – | – | ﹤0.01% | 493 |
|
|
2023
Q3 | $800 | Hold |
267
| – | – | ﹤0.01% | 516 |
|
|
2023
Q2 | $8.24K | Hold |
267
| – | – | ﹤0.01% | 443 |
|
|
2023
Q1 | $13.2K | Hold |
267
| – | – | ﹤0.01% | 401 |
|
|
2022
Q4 | $7K | Hold |
267
| – | – | ﹤0.01% | 446 |
|
|
2022
Q3 | $18K | Hold |
267
| – | – | ﹤0.01% | 385 |
|
|
2022
Q2 | $11K | Buy |
+267
| New | +$12K | ﹤0.01% | 409 |
|
Bangor Savings Bank's BCLI Position: Q4 2025 in Review
Bangor Savings Bank sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2025, closing a stake of 266 shares — an estimated $188 sold.
Bangor Savings Bank first reported a position in BCLI in Q2 2022 and held it in 13 quarters. The position peaked at $18K in Q3 2022. 0 funds tracked by Wall St. Rank hold BCLI as of Q4 2025.
- Bangor Savings Bank reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2025 after selling out during the quarter.
- Bangor Savings Bank sold 266 BRAINSTORM CELL THERAPUTC shares in Q4 2025, an estimated $188.
- Bangor Savings Bank first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2022 and held it in 13 quarters.
- Bangor Savings Bank's BRAINSTORM CELL THERAPUTC position peaked at $18K in Q3 2022.
- 0 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2025.
Based on Bangor Savings Bank's 13F filing for Q4 2025, filed 16 Jan 2026.